Siemens Healthineers is expanding access to modern urinalysis testing with the Atellica LumIQ Analyser1, a portable and scalable point-of-care instrument designed for use on the frontlines of patient care. The system, manufactured in Sudbury, United Kingdom, helps clinicians detect and monitor conditions such as kidney disease, urinary tract infections, pregnancy and diabetes, while enabling testing closer to the patient and providing earlier clinical insights than traditional laboratory based methods.
Chronic kidney disease affects more than 10% of the global population and for millions of people, it progresses silently until treatments such as dialysis or kidney transplant become necessary - often when options are limited and costs are high2. Early detection, intervention, and routine monitoring through urinalysis can help slow or stop disease progression2,3. In many care settings, testing still relies on visually reading reagent strips, a method that introduces variability in both test execution and result interpretation.
As the NHS continues to move diagnostics closer to patients and expand care in community settings, solutions such as the Atellica LumIQ Analyser can play an important role. By bringing reliable, laboratory‑quality urinalysis out of the central laboratory and into primary and community care, the analyser enables faster clinical decision‑making, simplifies testing workflows, and helps reduce avoidable hospital visits. At a time of sustained operational pressure across the NHS, technologies that standardise quality and deliver immediate results can support more integrated, decentralised models of care and improve the experience for both clinicians and patients.
“Visual read test strips have been the foundation of accessible urinalysis worldwide, but they are not without limitations,” said Mark Borley, head of Point-of-Care Diagnostics for Siemens Healthineers Great Britain and Ireland. “By digitising and automating the interpretation of our trusted reagent strips, we are making laboratory-quality accuracy more accessible, especially for at-risk populations. Reducing the manual burden on clinicians also helps minimise subjectivity and user error, supporting consistent and actionable results to drive better outcomes.”
“Manufacturing Atellica LumIQ here in the United Kingdom is a clear statement of our long‑term commitment to innovation and resilience in point-of-care diagnostics,” said Linda Cummings, managing director of Siemens Healthineers Sudbury. “By producing LumIQ at our Sudbury site, we bring together deep technical expertise, rigorous quality oversight and a highly skilled UK workforce to support reliable, near‑patient testing - including the NHS’s shift towards more accessible, community‑based diagnostics.”
Building on a decades-long legacy of leadership in urinalysis, Siemens Healthineers is advancing the category by pairing proven chemistry with intelligent, digital innovation. The analyser’s modular design enables care sites to scale testing capacity as demand grows, helping accelerate turnaround times and support faster clinical decision-making. By combining urinalysis and hCG pregnancy testing on a single analyser, users can streamline workflows at a low total cost of ownership.
Designed for decentralised testing environments outside of the laboratory, the system offers an intuitive user interface, compact footprint, and built-in Wi-Fi for seamless connectivity to hospital and laboratory information systems. When paired with Atellica Connect POC Insights or the POCcelerator Data Management System, point-of-care coordinators and administrators can oversee multiple analysers, access actionable insights, and support quality assurance and troubleshooting.
Two members of the Siemens Healthineers Sudbury manufacturing team holding the Atellica LumIQ Point-of-Care Analyser, showcasing the advanced, compact device designed for modern urinalysis testing.
